secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0000950170-21-005294
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports positive safety results from OASIS Phase 1/2a trial of CLS-AX for wet AMD; dose escalation to 0.5 mg
--------------------------------------------------------------------------------

- Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.
- Combined Cohorts 1 & 2 (n=11): 36% of patients had no retreatments for ≥3 months; 55% for ≥2 months.
- Mean best corrected visual acuity (BCVA) and central subfield thickness (CST) were stable in the first two cohorts.
- Safety Monitoring Committee approved escalation to Cohort 3 (0.5 mg CLS-AX); patient screening has begun.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/0000950170-21-005294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/clsd-20211221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer